Sex, haemoglobin and kidney disease: New perspectives

European Journal of Clinical Investigation, Supplement

Volumn 35, Issue 3, 2005, Pages 52-57

  Duncan, John A ^a,b   Levin, Adeera ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

Chronic kidney disease; Gender; Haemoglobin

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; HEMOGLOBIN; SEX HORMONE;

ADULT; AGED; ANEMIA; CARDIOVASCULAR DISEASE; CELL FUNCTION; CHRONIC KIDNEY DISEASE; ENDOTHELIUM CELL; FEMALE; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOMES RESEARCH; OXYGEN AFFINITY; OXYGEN DISSOCIATION CURVE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE;

EID: 28944437228     PISSN: 0960135X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01531.x     Document Type: Review

References (64)

1. Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 1994;4:1486-90.
2. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-54.
3. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-34.
4. London GM, Zins B, Pannier B, Naret C, Berthelot JM, Jacquot C et al. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 1989;36:878-82.
5. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac class and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000;35:1737-44.
6. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:1775-80.
7. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia. Arch Int Med 2002;162:1401-8.
8. Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Relationship between hematocrit and renal function in men and women. Kidney Int 2001;59:725-31.
9. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13:504-10.
10. K-DOQI Guideline 8. Association of level of GFR with anemia. Am J Kidney Dis 2002;39 (2 Suppl. 1):S120-7.
11. Besarab A, Levin A. Defining a renal anemia management period. Am J Kidney Dis 2000;36 (Suppl. 3):S13-23.
12. Ifudu O. Patient characteristics determining rHuEPO dose requirements. Nephrol Dial Transplant 2002;17 (Suppl. 5):38-41.
13. Pequignot JM, Spielvogel H, Caceres E, Rodriquez A, Sempore B, Pequignot J et al. Influence of gender and endogenous sex steroids on catecholaminergic structures involved in physiological adaptation to hypoxia. Eur J Physiol 1997;433:580-6.
14. Peschle C, Rappaport IA, Sasso GF, Condorelli M, Gordon AS. The role of estrogen in the regulation of erythropoietin production. Endocrinology 1973;92:358-62.
15. Meyers LD, Habicht JP, Johnson CL, Brownie C. Prevalences of anemia and iron deficiency anemia in Black and White women in the United States estimated by two methods. Am J Public Health 1983;73:1042-9.
16. Fried W, Jonasson O, Lang G, Schwartz F. The hematologic effect of androgen in uremic patients: study of packed cell Volume and erythropoietin responses. Ann Intern Med 1973;79:823-7.
17. Moriyama Y, Fisher JW. Effects of testosterone and erythropoietin on erythroid colony formation in human bone marrow cultures. Blood 1975;45:665-70.
18. Alexanian R. Erythropoietin and erythropoiesis in anemic man following androgens. Blood 1969;33:564-73.
19. Kennedy BJ, Gilbertson AS. Increased erythropoiesis induced by androgenic-hormone therapy. N Eng J Med 1957;256:719.
20. Navarro JF, Mora C. Androgen therapy for anemia in elderly uremic patients. Int Urol Nephrol 2001;32:549-57.
21. Dukes PP, Goldwasser E. Inhibition of erythropoiesis by estrogens. Endocrinology 1961;69:21-9.
22. Malgor LA, Fisher JW. Effects of testosterone on erythropoietin production in isolated perfused kidneys. Am J Physiol 1970;218:1732-6.
23. Humpeler E, Vogel S, Schobersberger W, Mairbaurl H. Red cell oxygen transport in man in relation to gender and age. Mech Ageing Dev 1989;47:229-39.
24. Monti JP, Brunet PJ, Berland YF, Vanuxem DC, Vanuxem PA, Crevat AD. Opposite effects of urea on hemoglobin-oxygen affinity in anemia of chronic renal failure. Kidney Int 1995;48:827-31.
25. Frankenfield DL, Rocco MV, Frederick PR, Pugh J, McClellan WM, Owen WF. Racial/ethnic analysis of elected intermediate outcomes for hemodialysis patients: results from the 1997 ESRD Core Indicators Project. Am J Kidney Dis 1999;34:721-30.
26. Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol 1997;8:1921-9.
27. Collins A, Ma J, Ebben J. Hospital length of stay is associated with hematocrit level. J Am Soc Nephrol 1997;8:190A.
28. Kausz AT, Obrador GT, Pereira BJG. Anemia management in patients with chronic renal insufficiency. Am J Kidney Dis 2000;36 (Suppl. 3):S39-S51.
29. Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int 2002;61 (Suppl. 80):S35-S38.
30. Ma J, Ebben J, Xia H, Collins A. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-9.
31. Mann JFE. What are the short-term and long-term consequences of anemia in CRF patients? Nephrol Dial Transplant 1999;14 (Suppl. 2):29-36.
32. Levin A. The relationship of haemoglobin level and survival: direct or indirect effects? Nephrol Dial Transplant 2002;17 (Suppl. 5):8-13.
33. Stevens L, Stigant C, Levin A. Should hemoglobin be normalized in patients with chronic kidney disease? Semin Dial 2002;15:8-13.
34. Ross SD, Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J. The effect of anemia treatment on selected health related quality of life domains: a systematic review. Clin Ther 2003;25:1786-805.
35. Marcus R, Krause L, Weber AB, Dominguez-Mejia A, Schork NJ, Julius S. Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study. Circulation 1994;90:928-36.
36. Shub C, Klein AL, Zachariah PK, Bailey KR, Tajik AK. Determination of left ventricular mass by echocardiography in a normal population: effect of age and sex in addition to body size. Mayo Clin Proc 1994;69:205-11.
37. Levy D, Andersen KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988;108:7-13.
38. Garavaglia GE, Messerli FH, Schmieder RE, Nunez BD, Orens S. Sex differences in cardiac adaptation to essential hypertension. Eur Heart J 1989;10:1110-4.
39. Messerli FH, Garavaglia GE, Schmieder RE, Sundgaard-Riise K, Nunez BD, Amodeo C. Disparate cardiovascular findings in men and women with essential hypertension. Ann Intern Med 1987;107:156-61.
40. Stokes J III, Kannel WB, Wolf PA, Dágostino RB, Cupples LA. Blood pressure as a risk factor for cardiovascular disease. The Framingham Study - 30 years of follow-up. Hypertension 1989;13 (Suppl. I):I13-8.
41. Silbiger SR, Neugarten J. The role of gender in the progression of renal disease. Adv Ren Replace Ther 2003;10:3-14.
42. Seliger SL, Davis C, Stehman-Breen C. Gender and the progression of renal disease. Curr Opin Nephrol Hypertens 2001;10:219-25.
43. Hannedouche T, Chauveau P, Kalou F, Albouze G, Lacour B. Factors affecting progression in advanced chronic renal failure. Clin Nephrol 1993;39:312-20.
44. Rosman JB, Langer K, Brandl M, Piers-Becht TPM, Van Der Hem GK, ter Wee PM et al. Protein-restricted diets in chronic renal failure: a four year follow-up shows limited indications. Kidney Int 1989;36 (Suppl. 27):S96-S102.
45. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garatinni S et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993;329:85-9.
46. Gaedeke J, Noble NA, Border WA. Angiotensin II and progressive renal insufficiency. Curr Hypertens Report 2002;4:403-7.
47. Peters H, Noble NA, Border WA. Transforming growth factor-beta in human glomerular injury. Curr Opin Nephrol Hypertens 1997;6:389-93.
48. 1 and angiotensin II in renal fibrosis. Hypertension 1998;31 (1Pt2):181-8.
49. 1 rather than blood pressure be the therapeutic target? Semin Nephrol 1997;17:455-66.
50. Kagami S, Kuhara T, Okada K, Kuroda Y, Border WA, Noble NA. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 1997;51:646-71.
51. Rossert JA, McClellan WM, Roger SD, Verbeelen DL, Hörl WH. Contribution of anemia to progression of renal disease: a debate. Nephrol Dial Transplant 2002;17 (Suppl. 1):60-6.
52. Falanga V, Martin TA, Takagi H et al. Low oxygen tension increases mRNA levels of alpha 1 procollagen in human dermal fibroblasts. J Cell Physiol 1993;157:408-12.
53. Tamamori M, Ito H, Hiroe M, Marumo F, Hata RI. Stimulation of collagen synthesis in rat cardiac fibroblasts by exposure to hypoxic culture conditions and suppression of the effect by natriuretic peptides. Cell Biol Int 1997;21:175-80.
54. Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000;58:2351-66.
55. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-31.
56. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001;98:4044-9.
57. Carlini RG, Alonzo EJ, Dominguez J, Blanca I, Weisinger JR, Rothstein M et al. Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 1999;55:546-53.
58. Akimoto T, Kusano E, Inaba T, Iimura O, Takahashi H, Ikeda H et al. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int 2000;58:269-82.
59. Westenfelder C, Biddle DL, Barankowski RL. Human, rat and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999;55:808-20.
60. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001;16:307-12.
61. Roth D, Smith RD, Schulman G, Steinman TI, Hatch FE, Rudnick MR et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994;24:777-84.
62. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997;77:176-85.
63. Duncan JA, Mitchell R, Djurdev O, Levin A. Gender specific hemoglobin may be more appropriate than absolute hemoglobin in the assessment of anemia in chronic kidney disease. Am Soc Nephrol 2002;13:463A.
64. Duncan JA, Mitchell R, Djurdev O, Levin A. Gender specific hemoglobin may be more appropriate than absolute hemoglobin in the assessment of anemia in chronic kidney disease. Nephrol Dial Transplant 2003;18:687-8 (Abstract).